Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($0.80), $0.10 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $1.21 million versus the consensus estimate of $2.66 million.

2025 Financial Guidance

Based on current operating plans, the Company expects its cash, cash equivalents and investments to fund operations into mid-2027.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Rothschild Redburn Reiterates Buy Rating on Nu Holdings (Nubank) (NU)
• Goldman Sachs Starts Geely Automotive Holdings Ltd. (175:HK) (GELYF) at Buy
• Citi Starts Maire Tecnimont (MT:IM) at Buy